Global Information
회사소개 | 문의 | 비교리스트

세계의 수혈 진단 시장 예측(2022-2027년)

Global Blood Transfusion Diagnostics Market - Forecasts from 2022 to 2027

리서치사 Knowledge Sourcing Intelligence
발행일 2022년 03월 상품코드 1071428
페이지 정보 영문 124 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 3,950 ₩ 5,710,000 PDF (Single User License)
US $ 4,550 ₩ 6,578,000 PDF (Multiple User License)
US $ 6,950 ₩ 10,048,000 PDF (Enterprise License)


세계의 수혈 진단 시장 예측(2022-2027년) Global Blood Transfusion Diagnostics Market - Forecasts from 2022 to 2027
발행일 : 2022년 03월 페이지 정보 : 영문 124 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 수혈 진단 시장 규모는 2020년에 24억 5,100만 달러로, 예측 기간 중 6.28%의 CAGR로 성장하며 2027년에는 37억 5,500만 달러에 달할 것으로 예측되고 있습니다.

세계의 수혈 진단 시장을 조사했으며, 시장의 개요, 시장 규모 및 예측, 동향, 성장요인 및 억제요인, 유형·기술·최종사용자·지역별 분석 및 경쟁 구도 등을 정리하여 전해드립니다.

목차

제1장 서론

  • 시장의 정의
  • 시장 세분화

제2장 조사 방법

  • 조사 데이터
  • 전제조건

제3장 개요

  • 조사 하이라이트

제4장 시장 역학

  • 시장 촉진요인
  • 시장 억제요인
  • Porter의 산업 분석
    • 공급측의 교섭력
    • 구매자의 교섭력
    • 신규 진출업체의 위협
    • 대체품의 위협
    • 업계의 경쟁 구도
  • 업계의 밸류체인 분석

제5장 세계의 수혈 진단 시장 분석 : 유형별

  • 서론
  • 기기
  • 키트·시약

제6장 세계의 수혈 진단 시장 분석 : 기술별

  • 서론
  • ELISA
  • 웨스턴 블로팅
  • 핵산 증폭
  • 기타

제7장 세계의 수혈 진단 시장 분석 : 최종사용자별

  • 서론
  • 병원과 클리닉
  • 진단 랩
  • 혈액은행

제8장 세계의 수혈 진단 시장 분석 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 남미
    • 브라질
    • 아르헨티나
    • 기타
  • 유럽
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 기타
  • 중동과 아프리카
    • 사우디아라비아
    • 아랍에미리트
    • 기타
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 태국
    • 대만
    • 인도네시아
    • 기타

제9장 경쟁 환경과 분석

  • 주요 기업과 전략 분석
  • 신규 기업과 시장 수익성
  • 합병, 인수, 합의 및 협업
  • 벤더 경쟁력 매트릭스

제10장 기업 개요

  • Quotient Ltd.
  • BAG Healthcare
  • Abbott
  • Immucor
  • Diasorin SPA
  • Bio-Rad Laboratories Inc.
  • Grifols S.A.
  • F. Hoffmann La Roche Ltd.
  • Beckman Coulter Inc.
  • DIAGAST
KSA 22.05.03

The global blood transfusion diagnostics market was valued at US$2.451 billion in 2020 and is expected to grow at a CAGR of 6.28% over the forecast period to reach a total market size of US$3.755 billion by 2027.

Blood transfusion diagnostics refers to testing conducted on blood and blood components prior to transfusion to patients. To avoid adverse reactions or infection transmission, each blood unit must be checked for blood group type and disease screening. It is an essential component of transfusion treatment since it offers vital information to healthcare practitioners and validates the compatibility of donor and recipient blood samples. Red blood cells are the most frequently transfused blood products. Molecular blood group diagnosis is one of the transfusion diagnostics. For patients who have antibodies against clinically relevant, uncommon, or weak antigens, molecular blood group diagnosis allows for safer blood storage and on-demand supplies.

Developing and underdeveloped countries lack proper blood banks, medical equipment required for blood transfusion, adequate conditions for blood storage, and a limited supply of blood in response to high demand. Hospitals lack the necessary amenities to deliver hygienic and safe transfusions. Thus, the escalating burden of chronic disorders and the rising need for donor screening are boosting the market's growth. Furthermore, the rising need for transfusions because of trauma, car accidents, and surgical procedures is favourably influencing the market.

The emergence of advanced molecular platforms by market leaders accelerates the transition from manual testing and equipment to semi-automated and fully automated devices. These automated systems have been critical in detecting transfusion transmissible infections (TTIs) in blood samples and can accurately remove human error throughout the transfusion procedure.

During the forecast period, North America is expected to be the largest regional market for the global blood transfusion diagnostics market. This dominance can be attributed to increased acceptance of the blood transfusion procedure, increased public awareness regarding blood donations, and developed healthcare infrastructure. According to data released by the National Center for Biotechnology Information, over 15 million blood units are transfused in the United States each year, with an estimated 85 million units transfused globally.

Growth Factors

  • Blood and blood components are in high demand.

The rising prevalence of blood-related conditions such as haemophilia, cancer, thrombocytopenia, and others, as well as chronic kidney disease (CKD), has increased the demand for blood transfusions. According to World Kidney Day estimates, about 850 million individuals worldwide will be suffering from kidney diseases in 2020. In addition, one out of every ten individuals has chronic kidney disease (CKD), which is predicted to become the sixth leading cause of death by the end of 2040. Furthermore, the growing number of patients suffering from anaemia necessitates red blood cell transfusion for treatment, which is further driving up the demand for blood transfusion diagnostics. The World Health Organization (WHO) estimates that anaemia affects around 1.62 billion people worldwide. This, together with increased awareness regarding blood safety from infectious diseases through various initiatives in developed and developing nations, is driving up demand for blood screening tests and other diagnostic instruments.

Restraints:

  • The high cost of instruments and a lack of infrastructure

Despite the rising prevalence of chronic blood disorders and increased demand for blood transfusions, several issues are impeding the market's growth. One of the causes is a lack of investment in healthcare infrastructure and strict government policies, particularly in developing nations when compared to developed countries. Furthermore, the high cost of tests, instruments, and reagents, along with a shortage of qualified professionals to handle automated diagnostic solutions, is one of the factors restraining the growth of the blood transfusion diagnostics market during the forecast period.

The Impact of COVID-19 on the Blood Transfusion Diagnostics Market:

The COVID-19 pandemic had a detrimental impact on the market. The outbreak reduced the number of voluntary blood donors and affected the global supply chain of medical equipment. Some of the primary problems encountered by blood banks and hospitals during the crisis included decreased donor inflow, a lack of staff personnel, a scarcity of blood units, and public anxiety over transfusion-transmitted COVID-19. According to the American Red Cross, the organisation lost around 46,000 blood unit donations due to the pandemic. In addition, a few donor locations saw a significant decrease in blood donations due to lockdowns and suspension of blood drives. However, by the third quarter of 2020, most countries had lifted lockdown and stay-at-home rules, resulting in an increase in blood donations and transfusion operations across all blood centres.

Competitive insight:

Officials from the State Blood Transfusion Council (SBTC) reported in September 2021 that supplies in Maharashtra blood banks would barely last a week. This drop was attributed to a decrease in blood donation camps, reduced donor footfall owing to the pandemic, and the closure of offices and institutions in the state.

The American Red Cross started a new nationwide initiative in September 2021 to reach out to more black blood donors in order to aid patients with sickle cell disease and improve health outcomes. Blood donations from individuals of the same race or ethnicity as well as blood type are the most reliable option to treat sickle cell patients.

Segmentation:

  • By Type

Instruments

Kits & Reagents

  • By Technology

ELISA

Western Blotting

Nucleic Acid Amplification

Others

  • By End-User

Hospitals & Clinics

Diagnostic Labs

Blood Banks

  • By Geography

North America

  • United States
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • France
  • Germany
  • Italy
  • Others

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Blood Transfusion Diagnostics Market Analysis, By Type

  • 5.1. Introduction
  • 5.2. Instruments
  • 5.3. Kits & Reagents

6. Global Blood Transfusion Diagnostics Market Analysis, By Technology

  • 6.1. Introduction
  • 6.2. ELISA
  • 6.3. Western Blotting
  • 6.4. Nucleic Acid Amplification
  • 6.5. Others

7. Global Blood Transfusion Diagnostics Market Analysis, By End-User

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Diagnostic Labs
  • 7.4. Blood Banks

8. Global Blood Transfusion Diagnostics Market Analysis, By Geography 

  • 8.1.  Introduction
  • 8.2.  North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. UK
    • 8.4.2. France
    • 8.4.3. Germany
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Thailand
    • 8.6.5. Taiwan
    • 8.6.6. Indonesia
    • 8.6.7. Others

9.  Competitive Environment and Analysis

  • 9.1. Major Players and Strategy Analysis
  • 9.2.  Emerging Players and Market Lucrativenessness
  • 9.3.  Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4.  Vendor Competitiveness Matrix

10. Company Profiles

  • 10.1. Quotient Ltd.
  • 10.2. BAG Healthcare
  • 10.3. Abbott
  • 10.4. Immucor
  • 10.5. Diasorin SPA
  • 10.6. Bio-Rad Laboratories Inc.
  • 10.7. Grifols S.A.
  • 10.8. F. Hoffmann La Roche Ltd.
  • 10.9. Beckman Coulter Inc.
  • 10.10. DIAGAST
Back to Top
전화 문의
F A Q